Clinical trials: Neoadjuvant Treatment
Gastric Cancer
Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer
Phase II single-arm study designed to evaluate the efficacy and safety of preoperative chemotherapy with FOLFIRINOX regimen. The investigators will include 27 patients with resectable locally advanced gastric cancer.
- Trial name
- FOLFIRINOX (NCT03825861)
- Testing
- FOLFIRINOX
- Where
- Brazil
- Volunteers
- 27 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Prostate Cancer, Prostate Cancer Patients
177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial
The goal of this clinical trial is to explore the efficacy and safety of darolutamide combined with 177Lu-PSMA-617 in treating high-risk localized prostate cancer patients who are scheduled to undergo radical prostatectomy.
- Trial name
- IUNU-PC-123 (NCT07677566)
- Testing
- Darolutamide combined with 177Lu-PSMA-617
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Esophageal Cancer
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
Esophageal cancer is one of the most common malignant tumors worldwide, with high invasiveness and lethality. Currently, the treatment for resectable locally advanced esophageal cancer mainly consists of a treatment model…
- Trial name
- NCT06889402
- Testing
- Neoadjuvant therapy with PD-L1 inhibitor
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer
Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer
The purpose of this trial is to evaluate efficacy and toxicity of either the combination of docetaxel, trastuzumab sc and pertuzumab (arm A) or trastuzumab emtansin (arm B).
- Trial name
- PREDIX HER2 (NCT02568839)
- Testing
- docetaxel + trastuzumab sc + pertuzumab, trastuzumab emtansin
- Where
- 7 sites in Sweden
- Volunteers
- 202 people
- Sponsor
- Thomas Hatschek
Colon Cancer, PCSK9 Inhibitor
Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer
This multicenter, randomized, open-label, blinded-endpoint Phase II trial assesses the efficacy and safety of tolecizumab (PCSK9 inhibitor) plus sintilimab/CapeOX chemoimmunotherapy as neoadjuvant treatment for pMMR/MSS locally…
- Conditions
- Colon Cancer, PCSK9 Inhibitor, Neoadjuvant Immunochemotherapy
- Trial name
- TRIUNITE-08 (NCT07840677)
- Testing
- Tafolecimab, Sintilimab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lung Transplant Rejection
Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients
Background/Rationale Acute rejection (AR) is common in the first year after lung transplantation. AR has usually been reversible with treatment, but it can trigger chronic rejection that is the leading causes of late morbidity…
- Trial name
- PHORLUCY (NCT03500575)
- Testing
- photopheresis
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
The probability to achieve CR with R-chemotherapy in patients failing a rituximab containing first line regimen is quite low, in particular in cases with non GCB profile.
- Trial name
- FIL_VERAL12 (NCT01805557)
- Testing
- R-DHAP, BR-DHAP
- Where
- 24 sites in Italy
- Volunteers
- 108 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Non Small Cell Lung Cancer
Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
This is a single arm, one center, phaseⅡ study evaluating efficacy and safety of erlotinib as neoadjuvent treatment in patients with EBUS confirmed stage ⅢA N2 NSCLC with activating EGFR mutation in exon 19 or 21.
- Trial name
- ML25444 (NCT01217619)
- Testing
- erlotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Baohui Han
Small-Cell Lung Cancer
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage…
- Trial name
- IMforte (NCT05091567)
- Testing
- Atezolizumab, Lurbinectedin, Carboplatin
- Where
- 93 sites in United States, Belgium and 11 more
- Volunteers
- 660 people
- Sponsor
- Hoffmann-La Roche
Borderline Resectable Pancreatic Cancer
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer
This study was a single-arm multicenter prospective phase II clinical study, designed to evaluate the efficacy and safety of neoadjuvant nab-paclitaxel combined with S-1 in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT03850769
- Testing
- nab-paclitaxel and S-1
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Triple Negative Breast Cancer
Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients
This study is to evaluate the efficacy and safety for dose-dense epirubicin hydrochloride with cyclophosphamide followed by nanoparticlealbumin-bound paclitaxel with PD-1 in neoadjuvant therapy for patients with triple-negative…
- Trial name
- NeoTENNIS (NCT04418154)
- Testing
- epirubicin hydrochloride, Cyclophosphamide, Albumin bound paclitaxel
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fudan University
Locally Advanced Rectal Cancer (LARC)
PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
This is a single-center, open-label, single-arm clinical study aimed at conducting a preliminary evaluation of the efficacy and safety of combining PCSK9 inhibitors and PD-1 inhibitors (dual inhibitors) with neoadjuvant…
- Trial name
- NCT06933251
- Testing
- Neoadjuvant Chemoradiotherapy Combined with PD-1 inhibitor Immunotherapy and PCSK9 Inhibitor Therapy
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Guangdong Provincial People's Hospital
Psoriasis
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with plaque-type psoriasis.
- Trial name
- NCT00230529
- Testing
- infliximab
- Volunteers
- 249 people
- Sponsor
- Centocor, Inc.
Malignant Female Reproductive System Neoplasm
Physiatry-Led Cancer Prehabilitation During Neoadjuvant Systemic Therapy to Improve Function in Stage III-IVA Gynecologic Cancer Patients
This clinical trial studies whether physiatry-led cancer prehabilitation can be used during systemic treatment before surgery (neoadjuvant systemic treatment [NST]) to improve function in stage III-IVA gynecologic cancer…
- Trial name
- NCT07608445
- Testing
- Educational Intervention, Goal Setting, Interview
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Rectal Neoplasms
Local Excision in Downstaged Rectal Cancer
Patients with T2T3 low rectal cancer (size =< 4 cm) received neoadjuvant treatment (50Gy in 5 weeks with concomitant chemotherapy.
- Trial name
- GRECCAR 2 (NCT00427375)
- Testing
- local rectal excision, total mesorectal excision
- Where
- 40 sites in France
- Volunteers
- 148 people
- Sponsor
- University Hospital, Bordeaux
Cytomegalovirus Disease, Kidney Transplant Infection
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease…
- Trial name
- NCT02439957
- Testing
- Brincidofovir, Valganciclovir
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Jazz Pharmaceuticals
Pancreas Adenocarcinoma (MSI-H), Pancreatic Cancer Resectable
A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)
Pancreatic cancer exhibits significant heterogeneity, which poses a major challenge in selecting the best treatment for patients from the very beginning of care.
- Trial name
- PRODIGE 104 B (NCT07592819)
- Testing
- mFOLFIRINOX (modified FOLFIRINOX)
- Volunteers
- 367 people
- Sponsor
- Institut Paoli-Calmettes
Non Small Cell Lung Cancer, Stage I Lung Cancer
High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer
This trial studies how well high dose vitamin A compound works in treating participants with non-small cell lung cancer that can be removed by surgery.
- Conditions
- Non Small Cell Lung Cancer, Stage I Lung Cancer, Stage Ib Lung Carcinoma, Stage IA Lung Carcinoma AJCC V7
- Trial name
- NCT03870529
- Testing
- Vitamin A Compound, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
This is a phase 2, multicenter, randomized, open-label study to estimate the efficacy of talimogene laherparepvec as a neoadjuvant treatment followed by surgery compared to surgery alone in subjects with completely resectable…
- Trial name
- NCT02211131
- Testing
- Talimogene Laherparepvec, Immediate surgical resection of melanoma lesion(s)
- Where
- 46 sites in United States, Australia and 7 more
- Volunteers
- 150 people
- Sponsor
- Amgen
Rectal Neoplasms
CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients
Although neoadjuvant radiotherapy greatly decreases local recurrence in locally advanced rectal cancer patients undergoing surgery, it inevitably results in short-term and long-term toxicities.
- Trial name
- NCT02288195
- Testing
- Oxaliplatin, capecitabine, Radiation
- Where
- China
- Volunteers
- 663 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.